ABSCI CORPORATION ABSI 深 滬
等待開盤 08-16 09:30:00 美东时间
2.93
-0.070
-2.33%
華盛通- 最 高3.025
- 今 開3.01
- 成交量 612.82万股
- 最 低 2.82
- 昨 收 3.00
- 總市值 4.22亿
- 52周最高 6.33
- 市盈率 靜 --
- 換手率 4.26%
- 52周最低 2.01
- 委 比 90.60%
- 總股本 1.44亿
- 歷史最高 31.53
- 量 比 1.00
- 振 幅 6.83%
- 歷史最低 1.1111
- 每 手 1
- 風險率 0.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Needham Maintains Buy on Absci, Lowers Price Target to $8
Needham analyst Gil Blum maintains Absci (NASDAQ:ABSI) with a Buy and lowers the price target from $9 to $8.
08-13 18:00
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Absci's Earnings: A Preview
Absci (NASDAQ:ABSI) is set to give its latest quarterly earnings report on Tues...
08-11 23:02
Almirall Selects Second Target In Absci Collaboration To Accelerate AI-Driven Therapeutics For Severe Skin Conditions
Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci's successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with
08-07 14:48
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
Almirall and Absci expand their AI Drug Discovery collaboration, with Almirall selecting a second target for dermatological treatments. The expansion follows successful delivery of AI-designed antibody leads against a difficult-to-drug target in the first phase. The partnership combines Absci's generative AI platform with Almirall's dermatology expertise to accelerate novel therapeutics for skin diseases. Absci is eligible for up to $650 million ...
08-07 06:00
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
Absci Corporation将于2025年8月12日收盘后公布2025年第二季度的业务更新及财务和运营结果。管理层将在美国东部时间下午4:30（太平洋时间下午1:30）举行电话会议讨论业务进展、财务结果和前景。投资者可以在公司投资者关系网站上收听直播，并在活动后观看重播。Absci致力于通过生成设计加速药物发现，其集成药物创建平台结合AI与合成生物学数据引擎，快速设计治疗难治性靶标的创新疗法。公司目前在研药物包括治疗炎症性肠病的ABS-101，以及治疗脱发的ABS-201。Absci总部位于华盛顿州温哥华，在纽约市和瑞士设有AI研究实验室和创新中心。
07-30 20:05
Morgan Stanley Maintains Overweight on Absci, Lowers Price Target to $6.4
Morgan Stanley analyst Vikram Purohit maintains Absci (NASDAQ:ABSI) with a Overweight and lowers the price target from $7 to $6.4.
07-28 20:54
Absci Launches $50M Public Stock Offering To Fund AI-Driven Drug Programs
Absci Corporation (NASDAQ:ABSI) ("Absci"), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, announced today that it has commenced an underwritten
07-25 04:55
Absci Announces Pricing of Public Offering of Common Stock
Absci Corporation announced the pricing of an underwritten public offering of 16,670,000 shares of its common stock at $3.00 per share, with an option for underwriters to purchase up to an additional 2,500,500 shares. Proceeds of approximately $50 million will fund internal programs, platform investments, and general corporate purposes. Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen are joint book-running managers. The offering is registere...
07-25 00:45
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on ...
07-21 22:16
